Trastuzumab-PROTAC conjugate (Ab-PROTAC 3) that spares HER2 negative cells and only target bromodomain-containing protein 4 (BRD4) in HER2 positive breast cancer cell lines (86, 87). This evidence concerns the gene ERBB2 and breast cancer.